Mersana Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Updates

NEXT STORY
Graybug Vision Presents Preclinical Results for GB-401, a Potential Sustained-Delivery Treatment of up to Six Months for Primary Open Angle Glaucoma, at the American Glaucoma Society Annual Meeting
PREV STORY
BioDelivery Sciences Announces Phase I Clinical Trial Results at the American Academy of Pain Medicine’s 36th Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Esperion Announces Commercial Availability of the NEXLETOL™ (bempedoic acid) Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare

author_avatar
NASDAQ Market News

CB2 Insights Addresses Massive Healthcare Gap in Florida with its Skylight Direct Primary Care Membership

author_avatar
NASDAQ Market News

The global vaccine contract manufacturing market by revenue is expected to grow at a CAGR of approx. 13% during the period 2020–2026

author_avatar
NASDAQ Market News